معرفی
Xiaodong Ma is a Researcher at Åbo Akademi University, actively contributing to the MADNESS Centre of Excellence (2024–2028), a materials-driven initiative addressing antimicrobial resistance. His work aligns with UN Sustainable Development Goals related to health and innovation.
Research Interests: Focused on advanced drug delivery systems, cancer therapeutics, and nanomedicine. Key areas include prodrug development, nanoparticle-based therapies, and biomaterials targeting cancers like gastric, ovarian, and pancreatic cancers. His innovations involve DNAzyme nanomachines, mitochondrial reprogramming, and metabolic therapy exploitation.
Publications (2020–2024): Over 14 peer-reviewed articles, with recent works emphasizing carrier-free delivery systems, immunomodulatory therapies, and metabolic pathway targeting. Notable contributions include Nature Communications and Advanced Functional Materials publications.
Project Leadership: Co-Investigator in the MADNESS project, collaborating with multidisciplinary teams across institutions. Research emphasizes translational applications in materials science and biomedicine.
Technical Expertise: Prodrug design, DNA-based nanotechnology, mitochondrial therapies, and cancer metabolism modulation. His work bridges pharmaceutical science with engineering for clinical applications.
